메뉴 건너뛰기




Volumn 16, Issue 1, 2017, Pages

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin;Erratum: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin. [Cardiovasc Diabetol. 16, (2017) (8)] DOI: 10.1186/s12933-016-0491-5

Author keywords

Dapagliflozin; Sodium glucose co transporter 2 inhibitor; Small dense low density lipoprotein cholesterol; High density lipoprotein 2 cholesterol; Lipoprotein subspecies

Indexed keywords

ERRATUM; ERROR;

EID: 85033772700     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0491-5     Document Type: Article
Times cited : (7)

References (1)
  • 1
    • 85010202013 scopus 로고    scopus 로고
    • Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
    • Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16:8. doi: 10.1186/s12933-016-0491-5.
    • (2017) Cardiovasc Diabetol , vol.16 , pp. 8
    • Hayashi, T.1    Fukui, T.2    Nakanishi, N.3    Yamamoto, S.4    Tomoyasu, M.5    Osamura, A.6    Ohara, M.7    Yamamoto, T.8    Ito, Y.9    Hirano, T.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.